Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Sclerosis, Scleroderma Clear all

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Tofacitinib, Placebo Oral Tablet; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Systemic Sclerosis
Interventions: online fatigue intervention; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung Disease
Interventions: Pomalidomide (CC-4047), Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more

Conditions: Scleroderma, Diffuse
Interventions: rapcabtagene autoleucel, rituximab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • San Pablo, California + 10 more

Conditions: Systemic Sclerosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Sclerosis, Systemic
Interventions: Placebo, tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 18 more

Conditions: Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions: Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC); Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more

Conditions: Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Interventions: tadalafil and ambrisentan upfront combination therapy; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Scleroderma, Systemic
Interventions: GSK2330811, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Buffalo, New York

Conditions: Systemic Scleroderma
Interventions: C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo; Drug
Lead sponsor: Prism Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York

Conditions: Systemic Sclerosis-associated Interstitial Lung Disease
Interventions: Abituzumab 1500 mg, Abituzumab 500 mg, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions: Oral Ifetroban, Oral Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more

Conditions: Scleroderma, Gastroparesis
Interventions: transcutaneous electroacupuncture; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Sclerosis
Interventions: Pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Depletion of CD3/CD19 in an autologous stem cell transplant; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 8 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions: KYV-101; Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2041
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Systemic Sclerosis
Interventions: rapamycin, methotrexate; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Scleroderma, Interstitial Lung Disease
Interventions: dabigatran etexilate; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Scleroderma, Diffuse
Interventions: AVID200; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ischemia
Interventions: ambrisentan; Drug
Lead sponsor: Soumya Chatterjee; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Online Fatigue Intervention Program for People With Scleroderma

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

Cardiac Safe Transplants for Systemic Sclerosis

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Microvascular and Fibrosis Imaging Study

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Abituzumab in SSc-ILD

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Rapamycin vs Methotrexate in Diffuse SSc

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet